Antiphospholipid syndrome tests look for an immune-related pattern that may help explain certain blood clots or pregnancy complications. One positive antibody result does not establish antiphospholipid syndrome (APS). The result becomes meaningful when a healthcare professional considers which antibodies are present, whether they persist, the laboratory method, medications, and the person's clinical history.[1]
Ulta Lab Tests offers access to relevant laboratory testing where available. Testing informs a healthcare conversation; it does not replace diagnosis, treatment, or urgent care.
For the broader testing framework, learn how inflammation and autoimmune blood tests differ. This guide focuses on APS interpretation.
APS is an acquired autoimmune disorder associated with abnormal blood clotting and certain pregnancy complications. Relevant antibodies can target proteins that bind to phospholipids, molecules involved in cell membranes and clotting reactions.[1]
APS can occur on its own or alongside systemic lupus erythematosus (SLE). It can affect veins, arteries, and small blood vessels. Potential consequences include deep-vein thrombosis, pulmonary embolism, stroke, and organ injury. Pregnancy-related APS can occur without a previous leg or lung clot.[2]
However, some people have antiphospholipid antibodies without developing APS. Fatigue, headache, or a positive antibody flag alone cannot establish the diagnosis.[2]
Testing is most useful when the clinical history creates a specific APS question and the result could change care. A clinician should decide whether testing is appropriate after a clot or pregnancy complication; not everyone needs a broad clotting-disorder panel.[3]
| History or finding | What needs clarification | Testing context |
|---|---|---|
| An unexplained, recurrent, or unusual blood clot | Whether an acquired autoimmune tendency may contribute | The three core antibody systems, with medication and timing review |
| Stroke at an unexpectedly young age | Whether APS is one possible explanation among several | Focused antibody evaluation alongside neurological and vascular assessment |
| Recurrent pregnancy loss, fetal death, or selected placental complications | Whether the pregnancy pattern is compatible with obstetric APS | Core antibodies interpreted with obstetric records |
| Low platelets or other findings in a person with suspected APS or lupus | Whether there is a broader immune or organ-related pattern | CBC, selected antibodies, and targeted clinical evaluation |
For lupus-specific interpretation, see Systemic Lupus Erythematosus Tests: Beyond a Positive ANA.
Seek care promptly for a newly painful, swollen limb. Call 911 for sudden difficulty breathing, chest pain with concerning symptoms, fainting, or stroke symptoms such as facial droop or speech difficulty. Do not wait for an APS panel or its repeat date.[4]
Functional clotting tests and antibody measurements provide different information.[1]
| Test or laboratory system | What it measures and why it matters | How results are interpreted |
|---|---|---|
| Lupus Anticoagulant Evaluation with Reflex | Looks for antibody effects on phospholipid-dependent clotting reactions. The listed evaluation uses LA-sensitive testing and dilute Russell's viper venom time, with follow-on testing when indicated. | A prolonged screening time alone does not establish LA. Confirmatory findings, medications, and laboratory comments matter. Reflex testing may add charges. |
| Cardiolipin IgG IgM Antibodies Test | Measures two antibody classes associated with APS. IgG and IgM are antibody classes. | An elevated result may support an APS evaluation. An isolated low positive may be transient; the level, persistence, and clinical history matter. |
| Beta-2-Glycoprotein I IgG IgA IgM Antibodies Test | Measures antibodies against beta-2 glycoprotein I, a phospholipid-binding protein. The IgG and IgM results are part of the core evaluation. | The linked product also measures IgA. IgA is outside the standard 2023 laboratory classification criteria and does not replace IgG, IgM, or LA testing. |
Check the contents of any panel before ordering. A product name containing “antiphospholipid” does not establish that all three core systems are included. Avoid ordering overlapping individual tests and a panel that already contains them. The Complete Guide to Lab Tests and Blood Work explains how individual tests, panels, confirmation, and monitoring differ.
Repeat testing helps distinguish a temporary antibody finding from a persistent pattern. Antiphospholipid antibodies can sometimes appear during infections or other temporary circumstances.
Persistence is generally assessed with positive results on at least two occasions separated by 12 weeks or more. Your clinician decides which findings to repeat and whether testing conditions were reliable.[5]
Keep both original reports, including dates, values, units, methods, and interpretive comments. When feasible, comparable methods make follow-up easier to interpret. The confirmation interval must never delay evaluation or treatment of an acute clot or an urgent pregnancy concern.
The name has two traps: LA does not necessarily mean that someone has lupus, and “anticoagulant” describes its effect in certain laboratory reactions. Its clinical association is often with clotting rather than bleeding.
A routine activated partial thromboplastin time, or aPTT, cannot substitute for a dedicated lupus anticoagulant evaluation. A prolonged result has several possible explanations, and a normal routine result does not exclude LA.
Warfarin, heparins, and direct oral anticoagulants such as apixaban and rivaroxaban can affect LA assays. Depending on the drug and method, a result may be falsely positive, falsely negative, or difficult to interpret. This is especially relevant after a clot, when medication may already have started.[6]
Before collection, provide the medication name, dose, and time of the last dose. The clinician and laboratory should determine an appropriate testing strategy. Do not skip, stop, or change an anticoagulant to obtain a “cleaner” test. A product page saying no fasting preparation is needed does not remove the need for medication review.
Start with the exact test, antibody class, units, laboratory cutoff, and interpretive comment. “Positive” can mean different things across methods. There is no universal “optimal APS antibody level” for self-treatment.
The 2023 research classification framework uses defined moderate and high antibody levels for particular ELISA methods. Those thresholds should not be applied indiscriminately to another laboratory platform or treated as a boundary between “healthy” and “has APS.”[1] Read How to Read and Understand Your Lab Results for help distinguishing reference intervals from clinical decision thresholds.
These terms count positive antibody systems, not every individual line on a report. Triple positivity means LA, anticardiolipin, and anti-beta-2 glycoprotein I are all positive. IgG and IgM positivity within one system does not itself mean double positivity.
EULAR identifies persistent LA, double or triple positivity, and persistently high antibody levels as features associated with a higher-risk profile. Risk still depends on prior events and other health factors; an antibody pattern does not predict precisely when a clot will happen.[7]
| Educational result pattern | What it may mean | What should happen next |
|---|---|---|
| One mildly positive antibody during an infection | A temporary finding is possible | Review the indication and plan appropriate confirmation |
| Persistent antibody positivity with a documented clot | A clinically important APS pattern may be present | Specialist review of the complete history, profile, and alternative causes |
| LA reported positive while taking rivaroxaban | Medication interference may affect interpretation | Laboratory and clinician review before accepting the result |
| Persistent triple positivity without a prior clot | A higher-risk antibody profile, without automatically establishing thrombotic APS | Individualized assessment, including pregnancy history and prevention needs |
| Negative core tests despite concerning clinical findings | APS may be less likely, but the clinical problem remains unexplained | Reassess timing, methods, competing diagnoses, and the need for specialist input |
These examples cannot determine an individual diagnosis or treatment.
No. Classification criteria help researchers assemble comparable groups. They are not a self-diagnosis score or a universal clinical exclusion rule.
A 2026 systematic review of 24 studies reported pooled sensitivity of approximately 74% and specificity of 99% for the 2023 classification criteria, with lower sensitivity in obstetric APS and substantial variation across studies. These figures describe the criteria's performance in the included populations, not the accuracy of an individual blood test. The article was published August 19, 2026.[8]
An APS evaluation can be relevant even when a person has never had a DVT or pulmonary embolism. Pregnancy-related presentations require their own history: the number and timing of losses, fetal findings, blood pressure, placental complications, and other possible explanations.
An isolated miscarriage or a positive antibody alone does not establish obstetric APS. The obstetric and laboratory evidence must fit together. A clinician may coordinate care with maternal-fetal medicine, rheumatology, or hematology when an APS pattern is suspected.[5]
Discuss prior complications before pregnancy when possible. During pregnancy or after delivery, severe headache, vision changes, chest pain, trouble breathing, or severe abdominal pain require prompt medical attention. Do not wait for a repeat antibody appointment.[9]
Supporting tests address blood-cell changes, organ involvement, or medication safety. They do not replace the antibody evaluation, and not every person needs all of them.
| Supporting test | What it measures | Possible finding and important limitation |
|---|---|---|
| Complete Blood Count with Differential and Platelets | Red cells, hemoglobin, white cells, and platelets | Low platelets or anemia may need investigation. Medication effects, bleeding, infection, and other conditions can produce similar findings; a normal count does not exclude APS. |
| Comprehensive Metabolic Panel Test | Kidney-related chemistry, electrolytes, liver markers, and proteins | Rising creatinine, reduced estimated filtration, or abnormal liver markers can affect evaluation and medication planning. These results do not identify APS as the cause. |
| Urinalysis Complete Test | Chemical and microscopic urine findings | Protein, blood, or abnormal sediment can prompt kidney or urinary evaluation. Infection, contamination, and other kidney diseases can cause abnormalities. |
| Protein Total Random Urine Test with Creatinine | Urine protein relative to urine creatinine | An increased ratio helps quantify protein loss when indicated. It cannot establish why protein is present or diagnose APS-related kidney disease. |
For deeper interpretation, use the CBC and Anemia Blood Tests pillar and Kidney Function Tests pillar. If lupus is clinically plausible, use the focused lupus guide to discuss targeted evaluation. Thyroid, nutrient, and cardiovascular testing should follow their own clinical indications rather than becoming automatic APS add-ons.
| Test | Appropriate role | Key boundary |
|---|---|---|
| Prothrombin Time with INR | Commonly used to monitor warfarin under a prescribed plan | It is not an APS antibody test. The treatment target and response belong to the treating clinician. |
| Activated Partial Thromboplastin Time Test | Evaluates part of the clotting process in selected clinical settings | A prolonged or normal result alone cannot confirm or exclude LA. |
| D-Dimer Quantitative Test | May help evaluate suspected acute venous thrombosis within a clinician-directed diagnostic pathway | It does not diagnose APS. An elevated result is nonspecific; it cannot replace appropriate imaging. |
In suspected DVT or pulmonary embolism, clinicians consider the probability of a clot before deciding how to use D-dimer and imaging. Patients with high clinical probability generally need imaging-based assessment. Self-ordering an outpatient test must not delay that evaluation.[10]
Extended antibody testing is a specialist decision when conventional findings leave a well-supported clinical question unresolved.
Follow-up focuses on preventing complications and monitoring treatment. Repeated antibody panels cannot substitute for an anticoagulation-safety plan.
For someone taking warfarin, PT/INR testing may be central. However, LA can affect some INR measurements, including certain point-of-care results. Unexpected or inconsistent values need review by the anticoagulation team; patients should not change doses independently.[11]
Blood counts and kidney or liver testing may be selected according to medication and organ risk. Blood pressure, smoking, diabetes, cholesterol, and estrogen exposure can also matter. Discuss these with the treating clinician rather than ordering an undirected “complete APS” wellness panel.[7]
Bring the required identification, requisition, medication list, and previous results, including relevant clot and pregnancy records.
The linked core antibody products do not list a fasting requirement. Companion tests may have different instructions: the linked CMP states that fasting is preferred but not required. Follow the instructions for the entire order and any individualized clinician guidance. Follow the collection instructions for urine specimens.
For practical ordering and collection guidance, read Direct-Access Lab Testing: How It Works and What to Expect.
Ulta Lab Tests lets eligible patients review testing options and current prices online and access results through a secure account. Testing through Quest Diagnostics is available for applicable orders. Insurance is not required; HSA/FSA payment may be available for eligible services. Verify the specific test, collection route, preparation, and any reflex charges before purchase.
Explore the APS testing category with your clinician's recommended list. Save the original laboratory report for review, including interpretive comments and any reflex results.
The core evaluation includes lupus anticoagulant testing, anticardiolipin IgG and IgM, and anti-beta-2 glycoprotein I IgG and IgM. They answer related but different questions. A clinician connects the profile with relevant clinical events and repeat findings. The linked beta-2 glycoprotein product also includes IgA, which has a different interpretive role.
No. One result may reflect a temporary antibody, a persistent finding without clinical APS, or part of a more important pattern. The antibody type, level, repeat result, medication context, and documented health history all matter. A clinician should explain what the result changes and whether confirmation or further evaluation is needed.
The interval helps establish that a positive antibody finding persists over time. Two positive results only days apart cannot establish that persistence. Your clinician decides which tests to repeat and how to handle interference. The interval is for antibody confirmation; it is not an instruction to postpone treatment or urgent care.
No. The name reflects the history of the laboratory finding, not a diagnosis of systemic lupus erythematosus. LA can occur with or without lupus. If symptoms or organ findings suggest a separate lupus evaluation, a clinician may recommend targeted testing. A positive LA result alone does not establish either lupus or APS.
Yes, obstetric APS can involve pregnancy complications without a prior DVT or pulmonary embolism. Assessment depends on the specific pregnancy events, persistent antibody findings, and other possible causes. Bring records showing gestational timing and complications to your clinician. Planning before another pregnancy can help coordinate any appropriate specialist assessment.
Yes. Certain anticoagulants can interfere with the clotting assays used to evaluate LA. The effect depends on the medication, its timing, and laboratory methods. Provide the exact medication information before testing. Your clinician and the laboratory should plan interpretation or an alternative strategy; never interrupt treatment on your own to improve a test result.
No. A CBC measures blood cells rather than the core antibody profile. A routine aPTT measures clotting time but cannot replace dedicated LA evaluation. Normal supporting results do not resolve every APS question. Conversely, abnormal counts or clotting times can have many causes and should not automatically be attributed to APS.
Relevant tests can be ordered online where available, through the service's applicable authorization process. APS testing benefits from clinician involvement because timing, medications, pregnancy history, and repeat results affect interpretation. Review the linked products and preparation details with your provider. Online ordering does not replace urgent assessment for possible clot symptoms.
Antiphospholipid syndrome tests answer a clinical question through the combined antibody profile, persistence, testing conditions, and clinical history. Supporting tests help assess blood cells, organs, and treatment safety.
Review the Ulta Lab Tests APS testing options with your healthcare professional, choose the tests appropriate to your question, and make a plan for interpreting and acting on the results.
Medical and commercial disclosure: This article provides general education. Ulta Lab Tests offers laboratory testing and includes product links relevant to the discussion. A qualified healthcare professional should select and interpret tests and direct diagnosis and treatment. Do not start, stop, or change medication based on this article or an isolated laboratory result.
| Category | Linked test | Role |
|---|---|---|
| Core APS laboratory evaluation | Lupus Anticoagulant Evaluation with Reflex | Functional clotting evaluation for lupus anticoagulant. |
| Core APS laboratory evaluation | Cardiolipin IgG IgM Antibodies Test | Anticardiolipin antibody measurements. |
| Core APS laboratory evaluation | Beta-2-Glycoprotein I IgG IgA IgM Antibodies Test | Includes the core IgG/IgM measurements and an additional IgA result. |
| Supporting blood-cell assessment | Complete Blood Count with Differential and Platelets | Blood-cell and platelet context. |
| Supporting organ-function assessment | Comprehensive Metabolic Panel | Kidney-related chemistry, liver markers, and other supporting information. |
| Supporting kidney and urine assessment | Urinalysis Complete | Urine findings that may warrant further evaluation. |
| Supporting kidney and urine assessment | Protein Total Random Urine Test with Creatinine | Quantifies urine protein relative to creatinine. |
| Treatment monitoring | Prothrombin Time with INR | Warfarin-monitoring context. |
| Other coagulation assessment | Activated Partial Thromboplastin Time Test | Routine clotting assessment; distinct from dedicated lupus anticoagulant testing. |
| Clinician-directed acute clot evaluation | D-Dimer Test | Separate acute-thrombosis context, rather than APS antibody evaluation. |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
